PMID- 18557726
OWN - NLM
STAT- MEDLINE
DCOM- 20081231
LR  - 20230124
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Print)
IS  - 1600-6135 (Linking)
VI  - 8
IP  - 8
DP  - 2008 Aug
TI  - Factors affecting success of thymus transplantation for complete DiGeorge 
      anomaly.
PG  - 1729-36
LID - 10.1111/j.1600-6143.2008.02301.x [doi]
AB  - Thymus transplantation shows promise for the treatment of athymia in complete 
      DiGeorge anomaly. This report reviews the effects of dose of thymus tissue, ABO 
      compatibility, HLA matching, culture conditions, age of donor and 
      immunosuppression of recipient on immune outcomes at 1 year after 
      transplantation. Forty-nine athymic subjects have been treated with cultured 
      postnatal allogeneic thymus tissue; 36 (73%) survive with only one subject on 
      immunosuppression at 1.5 years. Of 31 surviving subjects more than 1 year after 
      transplantation, 30 (97%) developed naive T cells, T-cell proliferative responses 
      to mitogens and a diverse T-cell receptor beta variable (TCRBV) repertoire. The 
      dose of thymus tissue, HLA matching and use of immunosuppression had 
      nonsignificant effects on these outcome variables. Removal of deoxyguanosine from 
      culture medium and length of culture did not adversely affect outcomes. Use of 
      thymus tissue from donors over 1 month of age, versus under 1 month, resulted in 
      higher total T-cell numbers (p = 0.03). However, this finding must be confirmed 
      in a prospective trial. Although subtle immune effects may yet be associated with 
      some of the factors tested, it is remarkable that consistently good immune 
      outcomes result despite variation in dose, HLA matching and use of 
      immunosuppression.
FAU - Markert, M L
AU  - Markert ML
AD  - Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. 
      marke001@mc.duke.edu
FAU - Devlin, B H
AU  - Devlin BH
FAU - Chinn, I K
AU  - Chinn IK
FAU - McCarthy, E A
AU  - McCarthy EA
FAU - Li, Y J
AU  - Li YJ
LA  - eng
GR  - R01 AI047040/AI/NIAID NIH HHS/United States
GR  - R01 AI054843/AI/NIAID NIH HHS/United States
GR  - UL1 RR024128/RR/NCRR NIH HHS/United States
GR  - M01 RR000030/RR/NCRR NIH HHS/United States
GR  - K12 HD043494/HD/NICHD NIH HHS/United States
GR  - FD-R-002606/FD/FDA HHS/United States
GR  - UL1 RR024128-01/RR/NCRR NIH HHS/United States
GR  - R01 AI 54843/AI/NIAID NIH HHS/United States
GR  - R21 AI 60967/AI/NIAID NIH HHS/United States
GR  - R01 AI 47040/AI/NIAID NIH HHS/United States
GR  - R21 AI060967/AI/NIAID NIH HHS/United States
GR  - M03 RR60/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20080628
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of 
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
RN  - 0 (ABO Blood-Group System)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - ABO Blood-Group System
MH  - DiGeorge Syndrome/*surgery
MH  - Female
MH  - HLA Antigens
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Thymus Gland/*transplantation
MH  - Treatment Outcome
PMC - PMC3667673
MID - NIHMS460880
COIS- The authors have no conflicting financial interests.
EDAT- 2008/06/19 09:00
MHDA- 2009/01/01 09:00
PMCR- 2013/05/30
CRDT- 2008/06/19 09:00
PHST- 2008/06/19 09:00 [pubmed]
PHST- 2009/01/01 09:00 [medline]
PHST- 2008/06/19 09:00 [entrez]
PHST- 2013/05/30 00:00 [pmc-release]
AID - S1600-6135(22)05544-7 [pii]
AID - 10.1111/j.1600-6143.2008.02301.x [doi]
PST - ppublish
SO  - Am J Transplant. 2008 Aug;8(8):1729-36. doi: 10.1111/j.1600-6143.2008.02301.x. 
      Epub 2008 Jun 28.